Rafferty Asset Management, LLC - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 3 filers reported holding CTI BIOPHARMA CORP in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$4,772,800
-46.0%
1,136,381
-22.8%
0.03%
-56.8%
Q4 2022$8,842,856
+39.0%
1,471,357
+34.6%
0.07%
+8.8%
Q3 2022$6,362,000
+143.6%
1,093,043
+149.8%
0.07%
+183.3%
Q2 2022$2,612,000437,6010.02%
Other shareholders
CTI BIOPHARMA CORP shareholders Q2 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 3,904,400$3,355,0002.31%
BVF INC/IL 6,929,690$5,955,0000.65%
CAXTON CORP 324,452$279,0000.32%
NEA Management Company, LLC 3,750,000$3,222,0000.23%
Orbimed Advisors 5,000,000$4,297,0000.07%
Fosun International Ltd 459,274$390,0000.03%
Paloma Partners Management Co 229,800$197,0000.00%
OXFORD ASSET MANAGEMENT LLP 127,602$110,0000.00%
LMR Partners LLP 54,931$47,0000.00%
Tower Research Capital LLC (TRC) 17,495$15,0000.00%
View complete list of CTI BIOPHARMA CORP shareholders